Hodgkin Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Herein, the authors present three cases of CML diagnosed within five years of treatment initiation for Hodgkin's Lymphoma (HL); one of the three patients had CML with atypical variant carrying a rare mutation with BCR-JAK2 fusion.
|
31366526 |
2019 |
Hodgkin Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ruxolitinib has single-agent activity against HL but does not act against PMBCL with or without JAK2 amplification.
|
31707975 |
2019 |
Hodgkin Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Copy number alterations in programmed cell death ligand 1 (PDL1 or CD274), programmed cell death 1 ligand 2 (PDCD1LG2 or PDL2), and Janus kinase 2 (JAK2) genes (chromosome 9p24.1) characterize Hodgkin lymphoma, resulting in high response rates to programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) blockade.
|
29902298 |
2018 |
Hodgkin Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We reported a heterozygous intronic c.1641 + 6 T > C JAK2 variant (rs182123615) found in two independent familial cases diagnosed with gastric lymphoma and Hodgkin lymphoma.
|
27106701 |
2016 |
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo.
|
24610827 |
2014 |
Hodgkin Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This has been observed in certain pediatric acute lymphoblastic leukemias and adult T-cell lymphoblastic leukemias, and overexpression of JAK2 seems to be important in Hodgkin lymphoma.
|
22869151 |
2013 |
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hence, JAK2 and JMJD2C cooperatively remodel the PMBL and HL epigenome, offering a mechanistic rationale for the development of JAK2 and JMJD2C inhibitors in these diseases.
|
21156283 |
2010 |
Hodgkin Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we show high expression of JAK2 in the tumor cells of lymphocyte-predominant Hodgkin lymphoma in 85% of cases and activation of JAK2 in 39% of cases.
|
17652621 |
2007 |
Hodgkin Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Fluorescence in situ hybridization analysis did not reveal involvement of the JAK2 gene, located at chromosome band 9p24, and previously shown to be amplified in Hodgkin lymphoma and primary mediastinal diffuse large B-cell lymphoma.
|
17460466 |
2007 |
Hodgkin Disease
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
In lymphocyte-predominant Hodgkin lymphoma SOCS1 function may thus be frequently impaired by mutations, and this may contribute to high JAK2 expression and activation of the JAK2/STAT6 pathway.
|
17652621 |
2007 |
Hodgkin Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
JAK2 V617F mutation is uncommon in non-Hodgkin lymphomas.
|
16321863 |
2006 |
Hodgkin Disease
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Our data confirm previous cytogenetic results from primary Hodgkin's tumors suggesting an important pathogenic role of REL and JAK2 in this disease.
|
12478664 |
2003 |
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The potentials of some recently developed new signal transduction inhibitors for the treatment of Hodgkin's lymphomas are discussed in greater detail and comprise agents directed against Janus kinase 2 (JAK 2); Signal Transducers and Activators of Transcription (STAT factors); agents directed against SH 2-domains: the fes/fps oncogene, Ras; protein kinase C (PKC) isotypes and means of inducing radiation or drug-induced apoptosis.
|
9926251 |
1998 |